The following text will provide a detailed account of the anti-tumor effects of PD-1/PD-L1 inhibitors in ES-SCLC patients and elaborate on more treatment regimens combining immune checkpoints for SCLC. This evidence concerns the gene PDCD1 and small cell lung carcinoma.